Olga G. Safronova
Research Subjects
Olga G. Safronova has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
V. A. Vavilin
Siberian Division of the Russian Academy of Medical Sciences
6 shared publicationsV. V. Lyakhovich
Siberian Division of the Russian Academy of Medical Sciences
6 shared publicationsL. F. Kaznacheeva
First Municipal Pediatric Clinical Hospital
3 shared publicationsM. B. Shtark
3 shared publicationsN. A. Manankin
First Municipal Pediatric Clinical Hospital
3 shared publicationsS. I. Makarova
Siberian Division of the Russian Academy of Medical Sciences
3 shared publications
Latest Publications
- Open Access
- 3 May 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0176939
The gene expression profile of a drug metabolism system and signal transduction pathways in the liver of mice treated with tert-butylhydroquinone or 3-(3'-tert-butyl-4'-hydroxyphenyl)propylthiosulfonate of sodium
Tert-butylhydroquinone (tBHQ) is a highly effective phenolic antioxidant used in edible oils and fats in foods as well as in medicines and cosmetics. TBHQ has been shown to have both chemoprotective and carcinogenic effects. Furthermore, it has potential anti-inflammatory, antiatherogenic, and neuroprotective activities. TBHQ induces phase II detoxification enzymes via the Keap1/Nrf2/ARE mechanism, which contributes to its chemopreventive functions. Nonetheless, there is growing evidence that biological effects of tBHQ may be mediated by Nrf2-independent mechanisms related to various signaling cascades. Here, we studied changes in gene expression of phase I, II, and III drug metabolizing enzymes/transporters as well as protein levels and activities of cytochromes P450 (CYPs) elicited by tBHQ and its structural homolog TS-13 in the mouse liver. Next, we carried out gene expression analysis to identify signal transduction pathways modulated by the antioxidants. Mice received 100 mg/kg tBHQ or TS-13 per day or only vehicle. The liver was collected at 12 hours and after 7 days of the treatment. Protein and total RNA were extracted. Gene expression was analyzed using Mouse Drug Metabolism and Signal Transduction PathwayFinder RT2Profiler™PCR Arrays. A western blot analysis was used to measure protein levels and a fluorometric assay was employed to study activities of CYPs. Genes that were affected more than 1.5-fold by tBHQ or TS-13 treatment compared with vehicle were identified. Analysis of the gene expression data revealed changes in various genes that are important for drug metabolism, cellular defense mechanisms, inflammation, apoptosis, and cell cycle regulation. Novel target genes were identified, including xenobiotic metabolism genes encoding CYPs, phase II/III drug metabolizing enzymes/transporters. For Cyp1a2 and Cyp2b, we observed an increase in protein levels and activities during tBHQ or TS-13 treatment. Changes were found in the gene expression regulated by NFκB, androgen, retinoic acid, PI3K/AKT, Wnt, Hedgehog and other pathways.
- 3 May 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (5) , e0176939
Open AccessThe gene expression profile of a drug metabolism system and signal transduction pathways in the liver of mice treated with tert-butylhydroquinone or 3-(3'-tert-butyl-4'-hydroxyphenyl)propylthiosulfonate of sodium
Tert-butylhydroquinone (tBHQ) is a highly effective phenolic antioxidant used in edible oils and fats in foods as well as in medicines and cosmetics. TBHQ has been shown to have both chemoprotective and carcinogenic effects. Furthermore, it has potential anti-inflammatory, antiatherogenic, and neuroprotective activities. TBHQ induces phase II detoxification enzymes via the Keap1/Nrf2/ARE mechanism, which contributes to its chemopreventive functions. Nonetheless, there is growing evidence that biological effects of tBHQ may be mediated by Nrf2-independent mechanisms related to various signaling cascades. Here, we studied changes in gene expression of phase I, II, and III drug metabolizing enzymes/transporters as well as protein levels and activities of cytochromes P450 (CYPs) elicited by tBHQ and its structural homolog TS-13 in the mouse liver. Next, we carried out gene expression analysis to identify signal transduction pathways modulated by the antioxidants. Mice received 100 mg/kg tBHQ or TS-13 per day or only vehicle. The liver was collected at 12 hours and after 7 days of the treatment. Protein and total RNA were extracted. Gene expression was analyzed using Mouse Drug Metabolism and Signal Transduction PathwayFinder RT2Profiler™PCR Arrays. A western blot analysis was used to measure protein levels and a fluorometric assay was employed to study activities of CYPs. Genes that were affected more than 1.5-fold by tBHQ or TS-13 treatment compared with vehicle were identified. Analysis of the gene expression data revealed changes in various genes that are important for drug metabolism, cellular defense mechanisms, inflammation, apoptosis, and cell cycle regulation. Novel target genes were identified, including xenobiotic metabolism genes encoding CYPs, phase II/III drug metabolizing enzymes/transporters. For Cyp1a2 and Cyp2b, we observed an increase in protein levels and activities during tBHQ or TS-13 treatment. Changes were found in the gene expression regulated by NFκB, androgen, retinoic acid, PI3K/AKT, Wnt, Hedgehog and other pathways.
- 3 June 2014
- Published by Springer Nature in Inflammation Research
- Vol. 63 (9) , 729-740
Water-soluble phenol TS-13 combats acute but not chronic inflammation
This study was conducted to evaluate the effect of the synthetic water-soluble phenolic antioxidant TS-13 (sodium 3-(4'-methoxyphenyl)propyl thiosulfonate), an inducer of the redox-dependent Keap1/Nrf2/ARE signaling system, in experimental models of acute and chronic inflammation. Acute local inflammation was induced by intraplantar carrageenan injection into rat hind paws, and acute systemic inflammation was modeled by intravenous zymosan injection (in rats) or LPS-induced endotoxic shock (in mice). Chronic inflammation was investigated in rat models of air pouch and collagen-induced arthritis. The effects of TS-13 treatment were estimated by changes in the intensity of inflammation (paw edema, liver infiltration, animal survival, exudation, and clinical score of arthritis) and by the effects on reactive oxygen species (ROS) generation by leukocytes from peripheral blood and inflammatory exudates. We found the significant increase in expression of mRNA, content of protein and activity of a well-characterized Nrf2 target enzyme glutathione S-transferase P1, as well as nuclear extract protein binding to the ARE consensus sequence in liver of mice fed with diet containing TS-13. TS-13 markedly attenuated carrageenan-induced paw edema, reduced blood granulocyte number and volume density of liver infiltrates in the systemic zymosan-induced inflammation model, and increased mice survival after lipopolysaccharide-induced septic shock. However, TS-13 administration did not influence cell and protein exudation into air pouches and suppressed clinical manifestation of collagen-induced polyarthritis only at early stages. Nevertheless, TS-13 inhibited the generation of ROS by leukocytes in all inflammation models. The data suggest that the anti-inflammatory effects of Keap1/Nrf2/ARE system are more prominent against acute innate-mediated inflammation than chronic immune inflammation. This narrows the potential therapeutic efficacy of ARE inducers in inflammation treatment.
- 3 June 2014
- Published by Springer Nature in Inflammation Research
- Vol. 63 (9) , 729-740
Water-soluble phenol TS-13 combats acute but not chronic inflammation
This study was conducted to evaluate the effect of the synthetic water-soluble phenolic antioxidant TS-13 (sodium 3-(4'-methoxyphenyl)propyl thiosulfonate), an inducer of the redox-dependent Keap1/Nrf2/ARE signaling system, in experimental models of acute and chronic inflammation. Acute local inflammation was induced by intraplantar carrageenan injection into rat hind paws, and acute systemic inflammation was modeled by intravenous zymosan injection (in rats) or LPS-induced endotoxic shock (in mice). Chronic inflammation was investigated in rat models of air pouch and collagen-induced arthritis. The effects of TS-13 treatment were estimated by changes in the intensity of inflammation (paw edema, liver infiltration, animal survival, exudation, and clinical score of arthritis) and by the effects on reactive oxygen species (ROS) generation by leukocytes from peripheral blood and inflammatory exudates. We found the significant increase in expression of mRNA, content of protein and activity of a well-characterized Nrf2 target enzyme glutathione S-transferase P1, as well as nuclear extract protein binding to the ARE consensus sequence in liver of mice fed with diet containing TS-13. TS-13 markedly attenuated carrageenan-induced paw edema, reduced blood granulocyte number and volume density of liver infiltrates in the systemic zymosan-induced inflammation model, and increased mice survival after lipopolysaccharide-induced septic shock. However, TS-13 administration did not influence cell and protein exudation into air pouches and suppressed clinical manifestation of collagen-induced polyarthritis only at early stages. Nevertheless, TS-13 inhibited the generation of ROS by leukocytes in all inflammation models. The data suggest that the anti-inflammatory effects of Keap1/Nrf2/ARE system are more prominent against acute innate-mediated inflammation than chronic immune inflammation. This narrows the potential therapeutic efficacy of ARE inducers in inflammation treatment.
- 24 November 2013
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 156 (1) , 63-65
Effects of Simvaglyzin and Atorvaglyzin on the Expression of 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase in Rat Liver
Activity and levels of protein and mRNA of 3-hydroxy-3-methyl-glutaryl-CoA reductase were estimated in rat liver after the administration of atorvastatin and simvastatin and their complexes with glycyrrhizic acid (atorvaglyzin and simvaglyzin). The amount of 3-hydroxy- 3-methyl-glutaryl-CoA reductase protein in rats decreased by 13 and 25% (p < 0.05) 24 h after treatment with atorvaglyzin and simvaglyzin, respectively. Activity of this enzyme decreased by 46% in rats treated with atorvaglyzin. The amount of messenger RNA in these groups significantly increased as compared to control group (untreated animals).
- 24 November 2013
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 156 (1) , 63-65
Effects of Simvaglyzin and Atorvaglyzin on the Expression of 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase in Rat Liver
Activity and levels of protein and mRNA of 3-hydroxy-3-methyl-glutaryl-CoA reductase were estimated in rat liver after the administration of atorvastatin and simvastatin and their complexes with glycyrrhizic acid (atorvaglyzin and simvaglyzin). The amount of 3-hydroxy- 3-methyl-glutaryl-CoA reductase protein in rats decreased by 13 and 25% (p < 0.05) 24 h after treatment with atorvaglyzin and simvaglyzin, respectively. Activity of this enzyme decreased by 46% in rats treated with atorvaglyzin. The amount of messenger RNA in these groups significantly increased as compared to control group (untreated animals).
- 1 August 2008
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 146 (2) , 206-209
Antioxidant and endothelium-stabilizing effects of simvaglyzin on rabbits with experimental hypercholesterolemia
Simvaglyzin, a complex compound of simvastatin and glycyrrhizic acid, administered to rabbits with experimental hypercholesterolemiain in doses equivalent to 66.6 and 40 µg/kg simvastatin exhibited antioxidant capacity (decreased the content of lipid peroxidation products in the blood by 27–41%) and endothelium-normalizing effect (decreased the level of von Willebrand factor and endothelin-1 by 26–58 and 21–29%, respectively, compared to 200 µg/kg simvastatin, p<0.05).
- 1 August 2008
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 146 (2) , 206-209
Antioxidant and endothelium-stabilizing effects of simvaglyzin on rabbits with experimental hypercholesterolemia
Simvaglyzin, a complex compound of simvastatin and glycyrrhizic acid, administered to rabbits with experimental hypercholesterolemiain in doses equivalent to 66.6 and 40 µg/kg simvastatin exhibited antioxidant capacity (decreased the content of lipid peroxidation products in the blood by 27–41%) and endothelium-normalizing effect (decreased the level of von Willebrand factor and endothelin-1 by 26–58 and 21–29%, respectively, compared to 200 µg/kg simvastatin, p<0.05).
- 1 March 2008
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 145 (3) , 317-319
Study of cholesterol-lowering effect and safety of simvaglisin on rabbit model of hypercholesterolemia
- 1 March 2008
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 145 (3) , 317-319
Study of cholesterol-lowering effect and safety of simvaglisin on rabbit model of hypercholesterolemia
- 1 April 2005
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 139 (4) , 431-433
Glutathione-S-Transferase Polymorphism and Clinical Features of Acute Drug Poisoning in Children
- 1 April 2005
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 139 (4) , 431-433
Glutathione-S-Transferase Polymorphism and Clinical Features of Acute Drug Poisoning in Children
- 1 November 2004
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 138 (5) , 460-462
Atopy parameters in asthmatic children increase with accumulation of null-alleles of glutathione-S-transferase M1
- 1 November 2004
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 138 (5) , 460-462
Atopy parameters in asthmatic children increase with accumulation of null-alleles of glutathione-S-transferase M1
- 1 October 2003
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 136 (4) , 388-391
Interaction of GSTM1, GSTT1, and GSTP1 Genotypes in Determination of Predisposition to Atopic Dermatitis
The frequency of individual genotypes GSTM1, GSTT1, and GSTP1 and haplotypes was determined in patients with atopic dermatitis and healthy children. The actual frequency of some haplotypes was far...
- 1 October 2003
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 136 (4) , 388-391
Interaction of GSTM1, GSTT1, and GSTP1 Genotypes in Determination of Predisposition to Atopic Dermatitis
The frequency of individual genotypes GSTM1, GSTT1, and GSTP1 and haplotypes was determined in patients with atopic dermatitis and healthy children. The actual frequency of some haplotypes was far...
- 1 July 2003
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 136 (1) , 73-75
Relationship between Glutathione S-Transferase P1 Polymorphism and Bronchial Asthma and Atopic Dermatitis
We determined the prevalence of GSTP1-Ile105 and GSTP1-Val105 alleles in patients with bronchial asthma and atopic dermatitis and healthy children of 2 groups (randomized and nonatopic control). The...
- 1 July 2003
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 136 (1) , 73-75
Relationship between Glutathione S-Transferase P1 Polymorphism and Bronchial Asthma and Atopic Dermatitis
We determined the prevalence of GSTP1-Ile105 and GSTP1-Val105 alleles in patients with bronchial asthma and atopic dermatitis and healthy children of 2 groups (randomized and nonatopic control). The...